Suppr超能文献

分析要点及标准化或统一血 PINP 和β-CTX 等参考骨转换标志物检测方法的计划。

Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood.

机构信息

Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Department of Clinical Chemistry, University of Liège, CHU de Liège, Domaine du Sart-Tilman, B-4000 Liège, Belgium.

出版信息

Clin Chim Acta. 2021 Apr;515:16-20. doi: 10.1016/j.cca.2020.12.023. Epub 2020 Dec 28.

Abstract

Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood have been designated as reference bone turnover markers in osteoporosis by the International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). The IFCC Committee on Bone Metabolism (C-BM) has examined current commercial assays and performed a multicentre study to examine the agreement between assays for PINP and β-CTX in serum and plasma. The results of these studies will inform our work towards the harmonization of PINP assays and the standardization of β-CTX assays in blood, with the development of common calibrators and reference measurement procedures in collaboration with the reagent manufacturing industry. Successful achievement of these goals will help develop universally acceptable practice guidelines for the management of osteoporosis with the inclusion of common reference intervals and treatment targets for PINP and β-CTX.

摘要

国际骨质疏松基金会 (IOF) 和国际临床化学和实验室医学联合会 (IFCC) 将血清单脯氨酸肽 (PINP) 和 I 型胶原 C 端肽 (β-CTX) 指定为骨质疏松症的参考骨转换标志物。IFCC 骨代谢委员会 (C-BM) 已经检查了当前的商业检测方法,并进行了一项多中心研究,以检查血清和血浆中 PINP 和 β-CTX 检测方法之间的一致性。这些研究的结果将为我们朝着协调 PINP 检测方法以及在血液中标准化 β-CTX 检测方法的方向提供信息,同时与试剂制造行业合作开发共同的校准品和参考测量程序。成功实现这些目标将有助于制定普遍可接受的骨质疏松症管理实践指南,其中包括 PINP 和 β-CTX 的共同参考区间和治疗目标。

相似文献

7
Harmonization of commercial assays for PINP; the way forward.PINP 商用检测试剂的标准化;前进之路。
Osteoporos Int. 2020 Mar;31(3):409-412. doi: 10.1007/s00198-020-05310-6. Epub 2020 Jan 23.

引用本文的文献

6
Clinical use of bone markers: a challenge to variability.骨标志物的临床应用:变异性带来的挑战。
Adv Lab Med. 2023 Aug 28;5(1):7-14. doi: 10.1515/almed-2023-0092. eCollection 2024 Mar.
7
[Not Available].[无可用内容]
Adv Lab Med. 2023 Jul 24;5(1):15-23. doi: 10.1515/almed-2023-0041. eCollection 2024 Mar.
9
The Use of Bone-Turnover Markers in Asia-Pacific Populations.骨转换标志物在亚太人群中的应用。
Ann Lab Med. 2024 Mar 1;44(2):126-134. doi: 10.3343/alm.2023.0214. Epub 2023 Oct 23.

本文引用的文献

1
Harmonization of commercial assays for PINP; the way forward.PINP 商用检测试剂的标准化;前进之路。
Osteoporos Int. 2020 Mar;31(3):409-412. doi: 10.1007/s00198-020-05310-6. Epub 2020 Jan 23.
5
Osteoporosis treatment: recent developments and ongoing challenges.骨质疏松症治疗:最新进展和持续挑战。
Lancet Diabetes Endocrinol. 2017 Nov;5(11):898-907. doi: 10.1016/S2213-8587(17)30188-2. Epub 2017 Jul 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验